Royalty Pharma plc
RPRX
$39.85
$0.320.80%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 7.90% | 7.71% | 0.05% | -0.41% | 5.29% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.90% | 7.71% | 0.05% | -0.41% | 5.29% |
| Cost of Revenue | 105.33% | -196.00% | -121.79% | 314.39% | -182.13% |
| Gross Profit | -24.63% | 140.92% | 4,551.33% | -36.13% | 205.70% |
| SG&A Expenses | 108.92% | 370.32% | 92.02% | 14.20% | -0.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 206.31% | 32.22% | -94.69% | 1,479.41% | -144.27% |
| Operating Income | -41.75% | -16.63% | 824.08% | -41.02% | 385.38% |
| Income Before Tax | -44.91% | -53.37% | 10,243.53% | -53.41% | 560.53% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -44.91% | -53.37% | 10,243.53% | -53.41% | 560.53% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 40.54% | 34.55% | -2,255.39% | 43.50% | -425.13% |
| Net Income | -47.02% | -70.42% | 4,888.47% | -57.88% | 654.34% |
| EBIT | -41.75% | -16.63% | 824.08% | -41.02% | 385.38% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -45.09% | -68.48% | 5,014.95% | -68.11% | 655.78% |
| Normalized Basic EPS | -53.68% | -24.14% | 254.13% | -52.54% | 736.64% |
| EPS Diluted | -45.18% | -68.63% | 5,042.45% | -68.08% | 658.56% |
| Normalized Diluted EPS | -52.66% | -24.42% | 254.61% | -36.41% | 747.40% |
| Average Basic Shares Outstanding | -3.52% | -6.10% | -2.93% | 32.09% | -0.18% |
| Average Diluted Shares Outstanding | -5.59% | -5.80% | -3.24% | -1.41% | -1.40% |
| Dividend Per Share | 4.76% | 4.76% | 4.76% | 5.00% | 5.00% |
| Payout Ratio | 0.91% | 2.32% | -0.98% | 1.49% | -0.86% |